Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.00645

Antibody-Directed Therapies: Towards a Durable and Tolerable Treatment Platform for CTCL – A Review

  • 1Columbia University Irving Medical Center, United States

Cutaneous T-cell lymphomas (CTCL) are a rare group of heterogenous disorders characterized by cutaneous involvement of monoclonal T-lymphocytes. Although indolent at early stages, CTCL can confer significant morbidity and mortality when advanced. There is an unmet need for tolerable and durable treatments with antibodies recently gaining promise. Here we review approved systemic therapies and discuss select antibodies in development.

Keywords: cutaneous t-cell, lymphomas, brentuximab vedodin, Mogamulizumab, Denileukin difitox, E7777, Alemtuzamab, TTI-621, afm-13, ARGX-110, IPH4102, antibody-directed therapy, Pembrolizumab, Nivolumab

Received: 23 Apr 2019; Accepted: 01 Jul 2019.

Edited by:

Basem M. William, The Ohio State University, United States

Reviewed by:

Belinda P. Simoes, University of São Paulo, Brazil
John C. Reneau, Michigan Medicine, University of Michigan, United States  

Copyright: © 2019 Khan and Sawas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. Ahmed Sawas, Columbia University Irving Medical Center, New York, NY 10027, New York, United States, as4386@columbia.edu